ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.90-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ICCC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 27.6 | 26.5 | 17.5 | 18.6 | 19.2 | 15.3 | 13.7 | 11.0 | 10.4 | 9.5 | 10.2 | 7.6 | 6.0 | 5.4 | 5.1 |
| Total Revenues | — | — | 26.5 | 17.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of Revenues | — | 16.2 | 18.6 | 13.6 | 10.9 | 10.6 | 8.5 | 7.0 | 5.8 | — | — | — | — | — | — | — |
| Gross Profit | 12.4 | 11.4 | 7.9 | 3.9 | 7.6 | 8.7 | 6.9 | 6.7 | 5.2 | 5.2 | 5.4 | 6.3 | 4.4 | 3.1 | 3.1 | 2.8 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 1.9 | 3.0 | 3.9 | 4.4 | 4.5 | 4.2 | 4.4 | 3.7 | 3.5 | 2.0 | 1.2 | 1.2 | 2.2 | 1.2 | 0.9 | 1.7 |
| Other Operating Expenses, Total | — | — | — | — | 0.2 | 0.3 | — | — | — | — | — | — | — | — | — | — |
| Operating Income | 3.9 | 1.6 | (1.6) | (5.7) | (2.3) | 0.3 | (1.4) | (1.0) | (1.4) | (0.2) | 0.9 | 2.1 | (0.2) | (0.0) | 0.2 | (0.6) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.5 | — | 0.5 | 0.3 | 0.3 | — | — | — | — | — | — | — | — | — | — |
| Interest & Investment Income | 0.2 | 0.2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (3.0) | (2.7) | (0.5) | (0.0) | — | — | — | — | — | — | — | 0.1 | 0.0 | (0.2) | (0.1) | (0.1) |
| Asset Writedown | — | 2.7 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 0.9 | (1.0) | (2.1) | (5.8) | (2.5) | (0.1) | (1.0) | (1.3) | (1.9) | (0.4) | 0.8 | 2.1 | (0.3) | 0.2 | 0.2 | (0.7) |
| Income Tax Expense | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 | 0.5 | (0.3) | 0.2 | 0.9 | (0.1) | 0.1 | 0.1 | (0.3) |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | (2.5) | (0.1) | (1.0) | — | — | — | — | — | — | — | — | — |
| Net Income | 0.8 | (1.0) | (2.2) | (5.8) | (2.5) | (0.1) | (1.0) | (1.3) | (2.3) | (0.2) | 0.5 | 1.2 | (0.2) | 0.1 | 0.1 | (0.4) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.09 | (0.12) | (0.26) | (0.75) | (0.32) | (0.01) | (0.14) | (0.19) | (0.42) | (0.03) | 0.12 | 0.40 | (0.06) | 0.04 | 0.03 | (0.14) |
| Diluted EPS | 0.09 | (0.12) | (0.26) | (0.75) | (0.32) | (0.01) | (0.14) | (0.19) | (0.42) | (0.03) | 0.12 | 0.38 | (0.06) | 0.04 | 0.03 | (0.14) |
| Basic Weighted Avg Shares | 9.1 | 9.0 | 8.2 | 7.7 | 7.7 | 7.6 | 7.2 | 6.8 | 5.5 | 4.9 | 4.2 | 3.0 | 3.0 | 3.0 | 3.0 | 3.0 |
| Diluted Weighted Avg Shares | 9.2 | 9.0 | 8.2 | 7.7 | 7.7 | 7.6 | 7.2 | 6.8 | 5.5 | 4.9 | 4.3 | 3.2 | 3.0 | 3.1 | 3.1 | 3.0 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 4.4 | — | (3.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | 3.9 | 1.6 | (1.6) | (5.7) | (2.3) | 0.3 | (1.4) | (1.0) | (1.4) | (0.2) | 0.9 | 2.1 | (0.2) | (0.0) | 0.2 | (0.6) |
| Effective Tax Rate | 7.8% | — | — | -0.1% | -0.3% | -13.3% | 1.0% | -2.2% | -24.8% | 61.7% | 33.0% | 41.2% | 34.6% | 42.8% | 53.4% | 41.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.